Literature DB >> 9012758

Scleroderma and related conditions.

H Mitchell1, M B Bolster, E C LeRoy.   

Abstract

Systemic sclerosis is a generalized disorder characterized by fibrosis and microvascular injury in affected organs. Despite being recognized nearly 250 years ago, knowledge regarding pathogenesis remains limited, and treatment remains directed at symptomatic improvement. Early recognition of systemic sclerosis, however, is important in order to monitor for specific disease complications (i.e., fibrosing alveolitis, scleroderma renal crisis) as well as initiate manifestation specific therapies that improve quality of life.

Entities:  

Mesh：

Year:  1997        PMID： 9012758     DOI： 10.1016/s0025-7125(05)70508-3

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN： 0025-7125            Impact factor:   5.456


  9 in total

Review 1.  Animal models for scleroderma: an update.

Authors:  Yan Zhang; Anita C Gilliam
Journal:  Curr Rheumatol Rep       Date:  2002-04       Impact factor: 4.592

2.  [Acrocyanosis: crucial symptom in a case of chronic diarrhea and weight loss].

Authors:  N Hackelsberger; T Schmidt; A Stein; W Schepp
Journal:  Internist (Berl)       Date:  2003-11       Impact factor: 0.743

Review 3.  Recognition and management of scleroderma in children.

Authors:  I Foeldvari; N Wulffraat
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  Centrosome proteins: a major class of autoantigens in scleroderma.

Authors:  I Gavanescu; D Vazquez-Abad; J McCauley; J L Senecal; S Doxsey
Journal:  J Clin Immunol       Date:  1999-05       Impact factor: 8.317

Review 5.  Comorbidity burden in systemic sclerosis: beyond disease-specific complications.

Authors:  Eleni Pagkopoulou; Alexandra Arvanitaki; Dimitrios Daoussis; Alexandros Garyfallos; George Kitas; Theodoros Dimitroulas
Journal:  Rheumatol Int       Date:  2019-07-12       Impact factor: 2.631

6.  A potential role for protease nexin 1 overexpression in the pathogenesis of scleroderma.

Authors:  D Strehlow; A Jelaska; K Strehlow; J H Korn
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

7.  Cardiac repolarization abnormalities and increased sympathetic activity in scleroderma.

Authors:  Orcun Ciftci; Ahmet Mesut Onat; Bunyamin Yavuz; Ali Akdogan; Kudret Aytemir; Lale Tokgozoglu; Levent Sahiner; Ali Deniz; Kemal Ureten; Guler Kizilca; Meral Calguneri; Ali Oto
Journal:  J Natl Med Assoc       Date:  2007-03       Impact factor: 1.798

8.  Abnormalities of heart rate turbulence and heart rate variability as indicators of increased cardiovascular risk in patients with systemic sclerosis.

Authors:  Adam R Poliwczak; Elżbieta Waszczykowska; Bożena Dziankowska-Bartkowiak; Katarzyna Dworniak-Pryca
Journal:  Postepy Dermatol Alergol       Date:  2019-02-26       Impact factor: 1.837

9.  Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients.

Authors:  Bozena Dziankowska-Bartkowiak; Elzbieta Waszczykowska; Anna Zalewska; Anna Sysa-Jedrzejowska
Journal:  Mediators Inflamm       Date:  2005-08-14       Impact factor: 4.711
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.